Self-Controlled Risk Interval Design
Cross-source consensus on Self-Controlled Risk Interval Design from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Benefits
Other
Other
Highlighted claims
- The study uses secondary healthcare data and a self-controlled risk interval design. — Postmarketing safety surveillance for GSK’s AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study
- Only vaccinated people who experience an outcome during prespecified risk or control intervals contribute to the inferential analysis. — Postmarketing safety surveillance for GSK’s AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study
- Because each person serves as their own control, the design controls for known and unknown confounders that are stable over time. — Postmarketing safety surveillance for GSK’s AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study
- Conditional Poisson regression will estimate incidence rate ratios during risk windows relative to control windows. — Postmarketing safety surveillance for GSK’s AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study
- The design is suitable for transient exposures such as vaccination and acute outcomes such as GBS, ADEM, and AF. — Postmarketing safety surveillance for GSK’s AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study